Daisuke Uchida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Daisuke Uchida has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Hideo Yoshida
Second Department of Oral and Maxillofacial Surgery, Tokushima University School of Dentistry, Tokushima, Japan and
4 shared publicationsNobuyuki Kuribayashi
Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, Tochigi 321‑0293, Japan
4 shared publicationsHitoshi Kawamata
Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine, Tochigi 321‑0293, Japan
3 shared publications- Hitoshi Kawamata
Department of Oral and Maxillofacial Surgery, Dokkyo Medical University School of Medicine
3 shared publications Mitsunobu Sato
Second Department of Oral and Maxillofacial Surgery, Tokushima University School of Dentistry, Tokushima, Japan and
3 shared publicationsTetsuya Tamatani
The University of Tokushima Graduate School
3 shared publications
Latest Publications
- 1 September 2018
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
- Vol. 30 (5) , 439-444
Oral and maxillofacial symptoms of patients with IgG4-related disease: The meaning of a labial minor salivary gland biopsy
- 1 September 2018
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
- Vol. 30 (5) , 439-444
Oral and maxillofacial symptoms of patients with IgG4-related disease: The meaning of a labial minor salivary gland biopsy
- 1 July 2018
- Published by Spandidos Publications in Oncology Reports
- Vol. 40 (1) , 303-308
Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells
We have previously demonstrated that the stromal cell-derived factor (SDF-1)/CXCR4 system is involved in the metastasis of head and neck cancer. Additionally, it has been revealed that the blockade of CXCR4 by subcutaneous daily injection with AMD3100, a CXCR4 antagonist, may be effective in preventing metastasis in CXCR4-related head and neck cancer. Recent investigations have suggested that AMD070, a novel orally bioavailable inhibitor of CXCR4, may be minimally invasive compared with AMD3100. In the present study, we examined the effect of AMD070 on metastasis induced by the SDF-1/CXCR4 axis in B88-SDF-1 oral cancer cells, which express high levels of SDF-1 and CXCR4. Although treatment with AMD070 did not affect the anchorage-dependent growth of B88-SDF-1 cells, it significantly suppressed the anchorage-independent growth. Moreover, the SDF-1/CXCR4-dependent migration and invasion of B88-SDF-1 cells was significantly inhibited following treatment with AMD070. Subsequently, we performed an experimental therapy using AMD070 to prevent the distant metastasis of B88-SDF-1 cells in vivo. Daily oral administration of AMD070 significantly inhibited the lung metastasis of B88-SDF-1 cells in nude mice. These results indicated that AMD070 could be useful as a novel orally bioavailable inhibitor of oral cancer metastasis.
- 1 July 2018
- Published by Spandidos Publications in Oncology Reports
- Vol. 40 (1) , 303-308
Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells
We have previously demonstrated that the stromal cell-derived factor (SDF-1)/CXCR4 system is involved in the metastasis of head and neck cancer. Additionally, it has been revealed that the blockade of CXCR4 by subcutaneous daily injection with AMD3100, a CXCR4 antagonist, may be effective in preventing metastasis in CXCR4-related head and neck cancer. Recent investigations have suggested that AMD070, a novel orally bioavailable inhibitor of CXCR4, may be minimally invasive compared with AMD3100. In the present study, we examined the effect of AMD070 on metastasis induced by the SDF-1/CXCR4 axis in B88-SDF-1 oral cancer cells, which express high levels of SDF-1 and CXCR4. Although treatment with AMD070 did not affect the anchorage-dependent growth of B88-SDF-1 cells, it significantly suppressed the anchorage-independent growth. Moreover, the SDF-1/CXCR4-dependent migration and invasion of B88-SDF-1 cells was significantly inhibited following treatment with AMD070. Subsequently, we performed an experimental therapy using AMD070 to prevent the distant metastasis of B88-SDF-1 cells in vivo. Daily oral administration of AMD070 significantly inhibited the lung metastasis of B88-SDF-1 cells in nude mice. These results indicated that AMD070 could be useful as a novel orally bioavailable inhibitor of oral cancer metastasis.
- 20 May 2018
- Published by Japanese Society of Oral and Maxillofacial Surgeons in Japanese Journal of Oral and Maxillofacial Surgery
- Vol. 64 (5) , 259-264
Long-term follow-up of osseous dysplasia involving a radiolucent cystic lesion in the mandible
We report a case of osseous dysplasia associated with a radiolucent cyst-like bone cavity in the molar region of the mandible. A 46-year-old Japanese woman visited our hospital because of a pain on the right side of the mandible. A bone biopsy of the lesion revealed osseous dysplasia. The cyst-like bone cavity lesion contained serous content. Branches of inferior alveolar nerve were observed, whereas no epithelial structure was found on the wall of the cavity. The radiopaque lesion was solid and contained fibrous bone, therefor we did not consider surgical intervention of this lesion. However, we considered surgical treatment for the cyst-like lesion by filling the bone cavity with platelet-rich plasma to stimulate bone healing. We concomitantly performed an apicoectomy for the involved teeth in the bone cavity. After a long-term follow-up (10 years), ossification was observed in the bone cavity in the molar region with no signs of recurrence, and the osseous dysplasia lesion in the premolar region was stable without showing signs of growth.
- 20 May 2018
- Published by Japanese Society of Oral and Maxillofacial Surgeons in Japanese Journal of Oral and Maxillofacial Surgery
- Vol. 64 (5) , 259-264
Long-term follow-up of osseous dysplasia involving a radiolucent cystic lesion in the mandible
We report a case of osseous dysplasia associated with a radiolucent cyst-like bone cavity in the molar region of the mandible. A 46-year-old Japanese woman visited our hospital because of a pain on the right side of the mandible. A bone biopsy of the lesion revealed osseous dysplasia. The cyst-like bone cavity lesion contained serous content. Branches of inferior alveolar nerve were observed, whereas no epithelial structure was found on the wall of the cavity. The radiopaque lesion was solid and contained fibrous bone, therefor we did not consider surgical intervention of this lesion. However, we considered surgical treatment for the cyst-like lesion by filling the bone cavity with platelet-rich plasma to stimulate bone healing. We concomitantly performed an apicoectomy for the involved teeth in the bone cavity. After a long-term follow-up (10 years), ossification was observed in the bone cavity in the molar region with no signs of recurrence, and the osseous dysplasia lesion in the premolar region was stable without showing signs of growth.
- 1 January 2017
- Published by Japanese Society of Oral and Maxillofacial Surgeons in Japanese Journal of Oral and Maxillofacial Surgery
- Vol. 63 (7) , 338-346
Clinical manifestations of 57 cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in our hospital and the effectiveness of surgical intervention in patients with BRONJ
- 1 January 2017
- Published by Japanese Society of Oral and Maxillofacial Surgeons in Japanese Journal of Oral and Maxillofacial Surgery
- Vol. 63 (7) , 338-346
Clinical manifestations of 57 cases of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in our hospital and the effectiveness of surgical intervention in patients with BRONJ
- 20 June 2016
- Published by Bentham Science Publishers Ltd. in Current Signal Transduction Therapy
- Vol. 11 (1) , 3-8
Chemoresistance of Cancer Cells: Oncogenic Mutation of the p53 Tumor Suppressor Gene
- 20 June 2016
- Published by Bentham Science Publishers Ltd. in Current Signal Transduction Therapy
- Vol. 11 (1) , 3-8
Chemoresistance of Cancer Cells: Oncogenic Mutation of the p53 Tumor Suppressor Gene
- Open Access
- 10 February 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (12) , 14310-14323
Overexpression of TSC-22 (transforming growth factor-β-stimulated clone-22) causes marked obesity, splenic abnormality and B cell lymphoma in transgenic mice
Overexpression of TSC-22 (transforming growth factor- β-stimulated clone-22) causes marked obesity, splenic abnormality and B cell lymphoma in transgenic mice
- 10 February 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (12) , 14310-14323
Open AccessOverexpression of TSC-22 (transforming growth factor-β-stimulated clone-22) causes marked obesity, splenic abnormality and B cell lymphoma in transgenic mice
Overexpression of TSC-22 (transforming growth factor- β-stimulated clone-22) causes marked obesity, splenic abnormality and B cell lymphoma in transgenic mice
- 31 July 2012
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 30 (2) , 133-142
Expression and function of CXCR4 in human salivary gland cancers
Salivary gland cancers (SGCs) frequently metastasize to cervical lymph nodes and distant organs. Currently, the mechanisms responsible for the metastatic behavior of SGC cells are not fully understood. We previously demonstrated that the stromal cell-derived factor-1 (SDF-1; also known as CXCL12)/CXCR4 system is involved in the establishment of metastasis in oral squamous cell carcinoma. In the present study, we investigated the role of CXCR4 in the metastatic behavior of SGCs. We examined the expression of CXCR4 mRNA and protein in human SGC cell lines by quantitative RT-PCR and western blotting, respectively. The expression of CXCR4 mRNA and protein were frequently upregulated in 5 out of 6 SGC cell lines. Functional CXCR4 expression was demonstrated by the ability of these SGC cell lines to migrate toward an SDF-1 gradient. SDF-1 rapidly activated extracellular signal-regulated kinase (ERK)1/2 in SGC cell lines. Immunohistochemical analysis revealed that CXCR4 protein expression was detected in either the nucleus or cytoplasm of cancer cells in 16 out of 20 tissues of adenoid cystic carcinoma (ACC) and in 4 out of 6 tissues of mucoepidermoid carcinoma, which are representative of SGC. Furthermore, ACC cell lines exhibited dramatic metastasis to the lung following intravenous inoculation, whereas AMD3100, a CXCR4 antagonist, significantly inhibited lung metastasis of the cells, ameliorated body weight loss and improved the survival rate of tumor-bearing nude mice. These results indicate that CXCR4 expression contributes to the metastatic potential of SGCs.
- 31 July 2012
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 30 (2) , 133-142
Expression and function of CXCR4 in human salivary gland cancers
Salivary gland cancers (SGCs) frequently metastasize to cervical lymph nodes and distant organs. Currently, the mechanisms responsible for the metastatic behavior of SGC cells are not fully understood. We previously demonstrated that the stromal cell-derived factor-1 (SDF-1; also known as CXCL12)/CXCR4 system is involved in the establishment of metastasis in oral squamous cell carcinoma. In the present study, we investigated the role of CXCR4 in the metastatic behavior of SGCs. We examined the expression of CXCR4 mRNA and protein in human SGC cell lines by quantitative RT-PCR and western blotting, respectively. The expression of CXCR4 mRNA and protein were frequently upregulated in 5 out of 6 SGC cell lines. Functional CXCR4 expression was demonstrated by the ability of these SGC cell lines to migrate toward an SDF-1 gradient. SDF-1 rapidly activated extracellular signal-regulated kinase (ERK)1/2 in SGC cell lines. Immunohistochemical analysis revealed that CXCR4 protein expression was detected in either the nucleus or cytoplasm of cancer cells in 16 out of 20 tissues of adenoid cystic carcinoma (ACC) and in 4 out of 6 tissues of mucoepidermoid carcinoma, which are representative of SGC. Furthermore, ACC cell lines exhibited dramatic metastasis to the lung following intravenous inoculation, whereas AMD3100, a CXCR4 antagonist, significantly inhibited lung metastasis of the cells, ameliorated body weight loss and improved the survival rate of tumor-bearing nude mice. These results indicate that CXCR4 expression contributes to the metastatic potential of SGCs.
- 1 May 2011
- Vol. 38 (5) , 777-81
[Evaluation of combination chemotherapy with oral S-1 administration followed by docetaxel by superselective intra-arterial infusion for patients with oral squamous cell carcinomas].
The purpose of this study was to evaluate the effectiveness and adverse events of combination chemotherapy with oral S-1 administration following docetaxel (DOC) treatment by superselective intra-arterial infusion as neo-adjuvant chemotherapy (NAC) for patients with oral squamous cell carcinoma. Thirteen patients were enrolled in this study (9 men and 4 women, with a mean age of 61. 0 years). All patients were given S-1 65mg/m(2) per day for 14 days, and DOC 40-50mg/m(2) by intraarterial infusion was administered. The locoregional response evaluated 3 weeks after administration was 100%, including a 69. 2% complete response. According to Oboshi and Shimosato's classification, histological evaluation of surgical specimens revealed that 3 cases were Grade II a, 4 cases Grade II b, 1 case Grade IV a, and 4 cases Grade IV c. The severe side effects were neutropenia and cerebral infarction. The present study suggests that combination chemotherapy with S-1 and DOC by superselective intra-arterial infusion would be an effective and safe regimen in NAC for oral squamous cell carcinomas.
- 1 May 2011
- Vol. 38 (5) , 777-81
[Evaluation of combination chemotherapy with oral S-1 administration followed by docetaxel by superselective intra-arterial infusion for patients with oral squamous cell carcinomas].
The purpose of this study was to evaluate the effectiveness and adverse events of combination chemotherapy with oral S-1 administration following docetaxel (DOC) treatment by superselective intra-arterial infusion as neo-adjuvant chemotherapy (NAC) for patients with oral squamous cell carcinoma. Thirteen patients were enrolled in this study (9 men and 4 women, with a mean age of 61. 0 years). All patients were given S-1 65mg/m(2) per day for 14 days, and DOC 40-50mg/m(2) by intraarterial infusion was administered. The locoregional response evaluated 3 weeks after administration was 100%, including a 69. 2% complete response. According to Oboshi and Shimosato's classification, histological evaluation of surgical specimens revealed that 3 cases were Grade II a, 4 cases Grade II b, 1 case Grade IV a, and 4 cases Grade IV c. The severe side effects were neutropenia and cerebral infarction. The present study suggests that combination chemotherapy with S-1 and DOC by superselective intra-arterial infusion would be an effective and safe regimen in NAC for oral squamous cell carcinomas.
- 21 October 2010
- Published by Elsevier in European Journal of Cancer
- Vol. 47 (3) , 452-459
Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases
- 21 October 2010
- Published by Elsevier in European Journal of Cancer
- Vol. 47 (3) , 452-459
Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases